Observation Of Short-term Clinical Curative Effect Of Selenium Enriched Yeast Combined With TACE In The Treatment Of HCC

Objective: through the application of selenium enriched yeast combined with TACE in the treatment of patients with primary liver cancer patients,determination of serum selenium level and serum vascular endothelial growth factor,treatment safety,efficacy and adverse reactions,for further study of selenium enriched yeast combined with anti tumor effect and mechanism of TACE by providing foundation.Information and methods1.patients: comparison of accepted treatment of liver cancer patients,a total of60 cases(male 46 cases,female 14 cases,age 28-70 years),all the cases,according to the visiting sequence.They were divided into A group and B group.The patients in group A were orally administered with TACE plus ordinary yeast,and the patients in group B were orally administered with TACE and selenium enriched yeast for 2months.2.observe index: observe the blood selenium content,serum VEGF,clinical efficiency,physical condition score and adverse reaction of two groups before and after treatment.3.statistical analysis: comparison between the two groups before and after treatment and whether there was significant difference in measurement data,mean standard deviation(x + s)said that the group by t test,count data rate(%)said that the2 test was used between groups,all data were analyzed using SPSS17.0 software package.P<0.05 said the difference was statistically significant.ResultAccording to the WHO objective evaluation criteria for solid tumors,the effective rate in group A was 40%,and B group was50%.There was a significant difference between the two groups before and after treatment,and there was no significant difference between B group and A group(P=0.7).The blood selenium levels in the two groups were not statistically significant before the treatment(P=0.428).After treatment,the mean blood selenium in group A was higher than that before treatment,which was significant(P=0.324).The mean blood selenium in group B was significantly higher than that before treatment,which was significant(P=0.000).Compared with the two groups,group B was higher than group A and had statistical significance(P=0.000).There was no significant difference in serum VEGF level between the two groups before treatment(P=0.597).After 5 days of treatment,the difference was notstatistically significant(P=0.578).The VEGF of group B decreased in 30 days after treatment,and the group A was still higher,and the difference was statistically significant(P=0.009).There was no statistical difference between the two groups before and after the treatment and between the two groups(P=0.267).The two groups of patients had no serious adverse reactions during the treatment,and the adverse reactions in the two groups were basically the same,and the difference was not statistically significant(P>0.05).Conclusion: 1.The blood selenium level of liver cancer patients is at a low level.After TACE treatment,blood selenium level can be improved,suggesting that tumor may lead to a decrease in blood selenium level,which may be related to tumor accumulation of blood selenium.Oral selenium supplementation can improve blood selenium level of patients.2,TACE treatment,found that the tumor volume significantly reduced,indicating that TACE can effectively control the liver cancer focus in the short term.TACE combined with selenium enriched yeast in the treatment of liver cancer,it is possible to improve the efficacy.3,TACE combined with selenium enriched yeast can reduce the level of serum VEGF after treatment,which can inhibit the progression of liver cancer and improve prognosis.4,in clinical practice,TACE combined with selenium enriched yeast is safe and feasible for the treatment of liver cancer.No severe toxic side effects are found.It has no effect on the physical performance of patients,and is expected to become a new treatment.